How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,084 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

into the study, females of childbearing potential (premenopausal women who are not permanently sterilized by means of hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) must commit to consistent and correct use of a highly effective method of birth control (true sexual abstinence, a vasectomized sexual partner, Implanon, female tubal occlusion, Intrauterine device (IUD), Depo provera injections, oral contraceptive pills or Nuvaring) for the duration of the trial and for 3 months after the last

2018 Clinical Trials

82. AMAZ-02 Effect on Exercise ToLerance in Healthy, Overweight Middle Aged Subjects (ATLAS Trial)

and have a negative urine pregnancy test result. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception

2018 Clinical Trials

83. Innate Neutrophilic Nasal Inflammation in a Pollen Exposure Chamber

have a negative urine pregnancy test at Visit 1. All females of child bearing potential must agree to a medically acceptable form of birth control throughout the study duration and for at least 1 month prior to Visit 1. Acceptable methods of birth control for this study include: oral, patch, or intra-vaginal contraceptives Norplant System® Depo-Provera® Intrauterine device (IUD) double barrier method abstinence surgically sterile females (hysterectomy or tubal ligation) > 1 year post-menopausal

2018 Clinical Trials

84. Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

-HCG) at screening and urine pregnancy at baseline. Female subjects of childbearing potential must be willing to use an acceptable form of birth control from the day of the first dose administration to 30 days after the last administration of IP. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (Medroxyprogesterone acetate-stabilized for at least 3 months); vaginal contraceptive

2018 Clinical Trials

85. UCSF College Health Study on Contraceptive Training and Education at Community Colleges

student knows these reversible methods including male condom, female condom, oral contraceptive pill, transdermal patch, vaginal ring, Depo-provera injectable, intrauterine device, subdermal implant, and emergency contraception. Secondary Outcome Measures : Change in student access to contraceptive services over 12 months, measured as whether student knows of or visited health services for contraceptives (questionnaire) [ Time Frame: Baseline, 12 months ] Change in willingness to use long-acting (...) contraceptive pill, transdermal patch, vaginal ring, Depo-provera injectable, intrauterine device, subdermal implant, and emergency contraception. The researchers will assess the outcome of student contraceptive knowledge by sociodemographic factors (age, race/ethnicity, parental education, health insurance, receipt of public assistance) and reproductive characteristics (parity, pregnancy intentions, male partner, prior contraceptive use). Sub-analyses for change in student access to contraceptive services

2018 Clinical Trials

86. Sculptra Aesthetic for the Treatment of Upper Knee Skin Laxity

form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms

2018 Clinical Trials

87. Intranasal Oxytocin and Food Intake in Obese Adolescents

(Child, Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Proficient in English. Pubertal or Post-Pubertal Females: 13 to <18 years. Pubertal or Post-Pubertal Males: 15 to <20 years. Girls must have a negative urine pregnancy test and post-menarchal girls must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study. Currently obese (BMI

2018 Clinical Trials

88. Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301

of contraception between the 2 visits. Approved forms of contraception include hormonal intrauterine devices, hormonal contraceptives (oral birth control pills, Depo-Provera®, patch, or other injectables) together with supplementary double-barrier methods, such as condoms or diaphragms with spermicidal gel or foam. The following categories define females who are NOT considered to be of childbearing potential: Premenopausal females with 1 of the following: Documented hysterectomy, Documented bilateral

2018 Clinical Trials

89. Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

. Administration of glucagon within 14 days of Screening. Pregnant and/or Lactating. For subjects of childbearing potential, there is a requirement for a negative urine pregnancy test and for agreement to use contraception and to refrain from breast feeding during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an intra-uterine device, the double barrier method (the female uses a diaphragm

2018 Clinical Trials

90. Low Dose Fat-Induced Insulin Resistance

Estimated glomerular filtration rate < 55 ml/min/1.73 m2 (calculated using the subject's measured serum creatinine and the Modification of Diet in Renal Disease [MDRD] study estimation formula). Presence of soy or egg allergies (due to possible reactions with fat infusate) For female participants: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices

2018 Clinical Trials

91. Benralizumab for Eosinophilic Gastritis

include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective IUD intrauterine device/IUS levonogestrel Intrauterine system, Depo-Provera(tm) injections, oral contraceptive, and Evra Patch(tm) or Nuvaring(tm). WOCBP must agree to use effective method of birth control, as defined above, from enrollment, throughout the study duration and within 16 weeks after last dose of IP, and have negative serum pregnancy test result on Visit 0

2018 Clinical Trials

92. People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

, an intrauterine device, Depo-Provera, or Norplant until 12 weeks post therapy. Current or prior history of any of the following: Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded. Gastrointestinal disorder or post-operative condition that could interfere

2018 Clinical Trials

93. Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

after the last study drug administration. Effective contraceptive methods include: Barrier methods such as condom, sponge or diaphragm combined with spermicide in foam, gel or cream; Hormonal contraception (oral, intramuscular, implant or transdermal) which include Depo Provera, Evra and Nuvaring; and Intrauterine device (IUD). Patients must be capable of giving informed consent and the consent must be obtained prior to any study related procedures. Exclusion criteria Patient with BSA > 15

2018 Clinical Trials

94. Reproductive Health Outcomes by Method of Breast Milk Feeding

pregnancy planning to initiate a hormonal contraceptive method at the postpartum visit At time of delivery hospitalization, a second eligibility verification will occur and women will be excluded if they: initiated a hormonal contraceptive method (specifically intrauterine device, implant, depo provera injections) during the delivery hospitalization had a hysterectomy did not deliver at UC Davis are no longer interested in study participation SUB-STUDY Inclusion Criteria: enrolled in the main study

2018 Clinical Trials

95. Primary Ovarian Insufficiency: Phenotype and Optimal Treatment

, etc.) Have an identified secondary cause of ovarian insufficiency Have POI in the setting of Turner syndrome, Fanconi Anemia, galactosemia, or Perrault syndrome (as associated neurological/medical sequelae could confound baseline measures) Have used medications known to affect bone metabolism over previous 3 months (e.g. anticonvulsants, chronic use of glucocorticords, Depo-Provera, oral contraceptive pills) Be currently pregnant (to be confirmed by pregnancy testing) Inclusion Criteria (...) of glucocorticoids, Depo-Provera, oral contraceptive pills, etc.) Have a learning disability or a developmental delay Be currently taking any SSRIs, antipsychotics or have any documented problems with anxiety or depression. Be currently pregnant (as confirmed by pregnancy testing) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer

2018 Clinical Trials

96. Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

options include: surgical sterilization (patient and/or patient's partner), approved hormonal contraceptives or therapies (such as birth control pills, Depo-Provera, or Lupron Depot), barrier methods (such as a condom or diaphragm) used with a spermicide, and an intrauterine device (IUD). Exclusion Criteria: Unwillingness or inability (such as coagulopathy) to undergo serial prostate biopsy. History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated

2018 Clinical Trials

97. Effects of Metformin During Nicotine Withdrawal

to enrollment. HIV-uninfected smokers: no diagnosis of HIV, either via blood test or self-report. Must not currently be interested in quitting smoking. Women of childbearing potential (based on medical history) must consent to use a medically accepted method of birth control (e.g., condoms and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, tubal ligation) or abstain from sexual intercourse during the time they are in the study and using transdermal nicotine. If current or past

2018 Clinical Trials

98. The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes

the study. Acceptable contraception methods include: Oral contraceptive pill (OCP), Intrauterine Device (IUD, hormonal or copper), Male condoms, Female condoms, Diaphragm or cervical cap with spermicide, Contraceptive patch (such as OrthoEvra), Contraceptive implant (such as Implanon, Nexplanon), Vaginal ring (such as NuvaRing), Progestin shot (such as Depo-Provera), Male partner with a vasectomy proven to be effective by semen analysis Need to go outside of the designated geographic boundaries during

2018 Clinical Trials

99. Timed Aspirin Chronobiome

the 3 months prior to screening. Female subjects of child bearing potential must be using a medically acceptable method of contraception (oral contraception, Depo-Provera injection, IUD, condom with spermicide, diaphragm, cervical cap, progestin implant, abstinence, tubal ligation, oophorectomy, TAH) throughout the entire study period. All female subjects must consent to a serum and urine pregnancy test at screening and close-out and a urine pregnancy test just prior to the start of each treatment

2018 Clinical Trials

100. Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir

participant report at Screening, regular menstrual cycles with at least 21 days between menses Note: This criterion is not applicable to participants who report using a progestin-only method of contraception at Screening (e.g., Depo-Provera or levonorgestrel-releasing IUD) nor to participants using continuous combination oral contraceptive pills, as the absence of regular menstrual cycles is an expected, normal consequence in this context. Per participant report at Screening and Enrollment, states

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>